PKU vs. Tay-Sachs: Comparing Two Genetic Neurodegenerative Disorders

Both phenylketonuria (PKU) and Tay-Sachs disease (TSD) are autosomal recessive inborn errors of metabolism causing neurological devastation if untreated, but they differ fundamentally in mechanism, treatability, and outcome.

Side-by-Side Comparison

Feature	PKU	Tay-Sachs Disease
Enzyme Deficiency	Phenylalanine hydroxylase (PAH)	β-Hexosaminidase A (HexA)
Accumulated Substrate	Phenylalanine (Phe)	GM2 ganglioside
Primary Toxicity	Phe & metabolites → neurotransmitter disruption, myelin impairment	GM2 in lysosomes → neuronal membrane disruption, apoptosis
Inheritance	Autosomal recessive (PAH gene, chr12)	Autosomal recessive (HEXA gene, chr15)
Newborn Screening	Universal (Guthrie test / tandem MS)	Not universal (pilot programs only)
Treatment	Dietary Phe restriction (lifelong) → normal development if early/continuous	No effective disease-modifying therapy; supportive only
Outcome if Treated	Normal IQ, lifespan	Progressive decline; death in childhood (infantile)
Outcome if Untreated	Severe ID, seizures, microcephaly, behavioral	Same as treated (no treatment exists)
Carrier Frequency (Ashkenazi)	~1/50	~1/30

Shared Neurological Features (Untreated)

• Intellectual disability / developmental regression
• Seizures
• Spasticity / motor deterioration
• Feeding difficulties
• Premature death

Key Differences

• Treatability: PKU is the paradigm of successful NBS + dietary therapy; TSD has no equivalent.
• Mechanism: PKU = toxic metabolite (small molecule) crossing BBB; TSD = lysosomal storage (macromolecule) within neurons.
• Reversibility: PKU brain damage largely preventable; TSD neuronal loss irreversible.
• Adult Phenylketonuria: Requires lifelong diet; maternal PKU syndrome (teratogenic) if uncontrolled in pregnancy.

Screening Implications

Universal PKU screening justified by actionable treatment. TSD screening targeted to high-risk populations (Ashkenazi Jewish, French Canadian, Cajun) for reproductive counseling, not neonatal intervention.